NCT01468896View on ClinicalTrials.gov

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 26, 2011

Primary Completion Date

September 29, 2015

Study Completion Date

March 19, 2026

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaUnresectable Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Cetuximab

Given IV

BIOLOGICAL

Edodekin alfa

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

20007

MedStar Georgetown University Hospital, Washington D.C.

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01468896 - Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter